CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-13 | Kewalramani Reshma CEO & President | Shares withheld for taxes | −5,990 | $298.26 | $1.8M | 148,714 |
| 2023-02-13 | Bozic Carmen EVP and CMO | Shares withheld for taxes | −4,992 | $298.26 | $1.5M | 70,265 |
| 2023-02-13 | Arbuckle Stuart A EVP, COO | Shares withheld for taxes | −5,990 | $298.26 | $1.8M | 86,890 |
| 2023-02-13 | Arbuckle Stuart A EVP, COO | Sale | −245 | $296.44 | $73K | 86,645 |
| 2023-02-13 | Arbuckle Stuart A EVP, COO | Sale | −2,028 | $298.42 | $605K | 84,617 |
| 2023-02-13 | Arbuckle Stuart A EVP, COO | Sale | −1,779 | $299.26 | $532K | 82,838 |
| 2023-02-13 | Arbuckle Stuart A EVP, COO | Sale | −835 | $300.13 | $251K | 82,003 |
| 2023-02-13 | ALTSHULER DAVID EVP, Global Research and CSO | Shares withheld for taxes | −5,990 | $298.26 | $1.8M | 59,194 |
| 2023-02-13 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −245 | $296.44 | $73K | 58,949 |
| 2023-02-13 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −2,160 | $298.47 | $645K | 56,789 |
| 2023-02-13 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −1,893 | $299.36 | $567K | 54,896 |
| 2023-02-13 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −500 | $300.23 | $150K | 54,396 |
| 2023-02-10 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Shares withheld for taxes | −2,707 | $294.33 | $797K | 70,183 |
| 2023-02-10 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes | −1,377 | $294.33 | $405K | 69,035 |
| 2023-02-10 | Sanna Bastiano EVP, Cell & Genetic Therapies | Shares withheld for taxes | −902 | $294.33 | $265K | 66,368 |
| 2023-02-10 | Sachdev Amit EVP, Chief Patient Officer | Shares withheld for taxes | −2,611 | $294.33 | $768K | 77,141 |
| 2023-02-10 | Kewalramani Reshma CEO & President | Shares withheld for taxes | −3,372 | $294.33 | $992K | 154,704 |
| 2023-02-10 | Bozic Carmen EVP and CMO | Shares withheld for taxes | −2,707 | $294.33 | $797K | 75,257 |
| 2023-02-10 | Arbuckle Stuart A EVP, COO | Shares withheld for taxes | −3,372 | $294.33 | $992K | 92,880 |
| 2023-02-10 | ALTSHULER DAVID EVP, Global Research and CSO | Shares withheld for taxes | −3,461 | $294.33 | $1.0M | 65,184 |
Page 37 of 40 · 781 trades